Trefoil Therapeutics Overview

  • Founded

  • 2013

Founded
  • Status

  • Private

  • Employees

  • 9

Employees
  • Latest Deal Type

  • Series A1

  • Latest Deal Amount

  • $12M

  • Investors

  • 12

Trefoil Therapeutics General Information

Description

Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.

Contact Information

Website
www.trefoiltherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 6330 Nancy Ridge Drive
  • Suite 103
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Trefoil Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trefoil Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A1) 22-Mar-2022 $12M 000.00 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 05-Aug-2019 0000 000.00 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series 1) 05-Jan-2017 00.00 00.00 00.00 Completed Startup
2. Grant 20-Oct-2015 Completed Startup
1. Accelerator/Incubator 01-Jan-2013 Completed Startup
To view Trefoil Therapeutics’s complete valuation and funding history, request access »

Trefoil Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series 1 18,551,984 $0.000100 7% $0.28 $0.28 1x $0.28 10.67%
To view Trefoil Therapeutics’s complete cap table history, request access »

Trefoil Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is
Biotechnology
San Diego, CA
9 As of 2022
000.00
000 0000-00-00
00000000000 000.00

0000 0

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000 00000

000000

rure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat null
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Trefoil Therapeutics Competitors (89)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
aTyr Pharma Formerly VC-backed San Diego, CA 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
0000000 Formerly VC-backed Calabasas, CA 00 0000 000000&0 0000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 Venture Capital-Backed Vienna, Austria 00.00 0000000000 00.00
You’re viewing 5 of 89 competitors. Get the full list »

Trefoil Therapeutics Patents

  • 9

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Trefoil Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3619324-A4 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 000000000 0
US-11479591-B2 Recombinant modified fibroblast growth factors and therapeutic uses thereof Active 05-May-2017 000000000 00
US-20200190158-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Active 05-May-2017 000000000
AU-2018261021-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 0000000000
CA-3062473-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 05-May-2017 A61K38/179
To view Trefoil Therapeutics’s complete patent history, request access »

Trefoil Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
David Eveleth Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Schalon Newton Chief Business Officer
Michael Blaber Ph.D Co-Founder & Scientific Advisory Board Member
Kenneth Thomas Ph.D Co-Founder, Scientific Advisory Member & Consultant
Mark Packer MD Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Trefoil Therapeutics Board Members (8)

Name Representing Role Since
Benjamin McGraw III Self Executive Chair of the Board 000 0000
Christy Shaffer Ph.D Hatteras Venture Partners Board Member 000 0000
David Eveleth Ph.D Trefoil Therapeutics Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Derek Yoon AJU IB Investment Board Member 000 0000
Liam Ratcliffe Ph.D Access Biotechnology Board Observer 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Trefoil Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trefoil Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Solasta Ventures Venture Capital Minority 000 0000 000000 0
Access Biotechnology Corporate Venture Capital Minority 000 0000 000000 0
Bios Partners Venture Capital Minority 000 0000 000000 0
FemHealth Ventures Venture Capital Minority 000 0000 000000 0
AJU IB Investment Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial